3562-99-0 Usage
Uses
Used in Pharmaceutical Industry:
3-(4-METHOXY-1-NAPHTHOYL)PROPIONIC ACID is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs targeting specific medical conditions.
Used in Chemical Research:
In the field of chemical research, 3-(4-METHOXY-1-NAPHTHOYL)PROPIONIC ACID serves as a valuable compound for studying the properties and reactions of naphthyl and methoxy groups. It can be used to explore new reaction pathways and develop novel synthetic methods.
Used in Veterinary Medicine:
3-(4-METHOXY-1-NAPHTHOYL)PROPIONIC ACID is used as a cholerectic compound for stimulating gastrointestinal function in animals, including cattle, sheep, goats, horses, and dogs. It promotes bile secretion, which can be beneficial in the treatment of hepatic dysfunction in dogs.
Used in Drug Delivery Systems:
Similar to gallotannin, 3-(4-METHOXY-1-NAPHTHOYL)PROPIONIC ACID can be employed in the development of drug delivery systems to enhance its bioavailability and therapeutic outcomes. By incorporating it into various carriers such as organic and metallic nanoparticles, its delivery and efficacy can be improved for specific applications.
Originator
Hepalande, Delalande ,W. Germany ,1977
Manufacturing Process
395 parts of (α-methoxynaphthalene and 265 parts of succinic anhydride are dissolved in 8,000 parts of dry benzene at room temperature. The resulting solution is stirred and 710 parts of anhydrous aluminum chloride are added over a period of twenty minutes. During the addition the temperature of the reaction mixture rises to about 60°C to 70°C. After the addition the reaction mixture is stirred for fifteen or twenty minutes at 60°C to 70°C and then refluxed for one hour. The hot reaction mixture is then poured onto a mixture of 5,000 parts of ice and 900 parts of concentrated hydrochloric acid. The benzene is removed by steam distillation and the hot aqueous residue is filtered to remove the insoluble β-(1-methoxy-4-naphthoyl)-propionic acid. The residue of the latter is dried and then dissolved in 16,000 parts of hot water containing 300 parts of sodium carbonate. The hot solution is treated with activated charcoal, filtered while hot, chilled and acidified. The residue of purified acid is collected on a filter, washed with water, and dried at 65°C. A yield of 552 parts of purified β-(1-methoxy)-4-naphthoyl)propionic acid, melting at 172°C to 173°C is obtained.
Therapeutic Function
Choleretic
Check Digit Verification of cas no
The CAS Registry Mumber 3562-99-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,5,6 and 2 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 3562-99:
(6*3)+(5*5)+(4*6)+(3*2)+(2*9)+(1*9)=100
100 % 10 = 0
So 3562-99-0 is a valid CAS Registry Number.
InChI:InChI=1/C14H12O3/c15-13(8-9-14(16)17)12-7-3-5-10-4-1-2-6-11(10)12/h1-7H,8-9H2,(H,16,17)
3562-99-0Relevant articles and documents
Multi-Targeting Tacrine Conjugates with Cholinesterase and Amyloid-Beta Inhibitory Activities: New Anti-Alzheimer's Agents
Hiremathad, Asha,Chaves, Sílvia,Keri, Rangappa S.
, (2021)
Alzheimer's disease (AD) is a severe age dependent and chronic problem with no cure so far. The available treatments are temporary, acting over short period of time. The main pathological hallmark of the disease includes cholinergic dysfunction, oxidative stress, accumulation of Aβ fibrils and tau tangles. In context with the multi-factorial nature of this disease, two different series of molecules were developed to hit the multifactorial disease targets. Mainly, the molecules were designed to inhibit the AChE and aggregation of Aβ, and also oxidative damage. Two novel series of TAC-fenbufen/menbutone conjugated molecules were designed, synthesized and bio-assayed. All compounds showed inhibition capacity towards AChE, Aβ aggregation and moderate to good radical scavenging capacity. Particularly, five TAC-menbutone molecules showed improved AChE and Aβ aggregation inhibition capacity compared to TAC-fenbufen conjugated molecules. Overall, these novel series of molecules may be potential drug lead molecules in the treatment of AD.
Improved meng Butong method for the synthesis of
-
Paragraph 0016-0018, (2017/04/14)
The invention discloses an improved synthesis method of menbutone. The method specifically comprises the following steps: dissolving 1-methoxy naphthalene and succinic anhydride in dichloromethane, cooling to 1-3 DEG C under stirring, slowly adding aluminum trichloride, heating solution to 35+/-2 DEG C, reacting in thermal insulation for 5.5-6.5 hours, pouring the reaction solution in an ice water mixture after the thermal insulation reaction, stirring, standing, crystallizing and suction-filtering, wherein the filter cake is a menbutone crude product; heating and distilling the filtrate to recycle dichloromethane; and then recrystallizing the menbutone crude product by using water as a solvent, and decoloring through activated carbon to obtain a menbutone competitive product. The synthesis method disclosed by the invention is simple, dichloromethane, which is the class 2 solvent with small use toxicity and high security degree, is used, the damage on the operator and environment is small, the solvent can be recycled, and the fished product yield is high to 86.4%; the synthesis method can be used for industrially synthesizing menbutone, and has good environment benefit and economic benefit.
